**Genomic Test activity**

**June 2025 Statistical Commentary**

**Main Findings**

This section will focus on main findings at a national level. Sub-national level data is available within the data set.

**Activity**

* The total number of reports in Q4 2024-2025 is 214,932, which is an increase of 3,369 (1.58%) in comparison to Q4 2023-2024.
* The total number of cancer reports in Q4 2024-2025 is 127,971, which is an increase of 14,749 (12.23%) in comparison to Q4 2023-2024.
	+ The total number of paediatric and TYA cancer reports in Q4 2024-2025 is 14,494, which is a decrease of 1,398 (10.13%) in comparison to Q4 2023-2024.
	+ The total number of adult cancer reports in Q4 2024-2025 is 113,299, which is an increase of 14,308 (13.48%) in comparison to Q4 2023-2024.
* The total number of rare and inherited disease reports in Q4 2024-2025 is 86,506, which is an decrease of 3,043 (3.46%) in comparison to Q4 2023-2024.

	+ The total number of paediatric rare and inherited disease reports in Q4 2024-2025 is 26,213, which is a decrease of 7,576 (25.25%) in comparison to Q4 2023-2024.
	+ The total number of adult rare and inherited disease reports in Q4 2024-2025 is 59,470, which is an increase of 5,280 (9.29%) in comparison to Q4 2023-2024.
* The total number of cancer whole genome sequencing reports in Q4 2024-2025 is 795, which is a decrease of 6 (0.75%) in comparison to Q4 2023-2024.
* The total number of rare and inherited disease whole genome sequencing reports in Q4 2024-2025 is 11,065, which is an increase of 1,954 (19.37%) in comparison to Q4 2023-2024.

**Background**

The national genomic testing service is delivered through a network of seven NHS Genomic Laboratory Hubs (GLHs), each responsible for coordinating services for a particular part of the country.

The seven NHS GLHs are:

* Central and South Genomic Laboratory Hub led by Birmingham Women’s and Children’s NHS Foundation Trust
* East Genomic Laboratory Hub led by Cambridge University Hospitals NHS Foundation Trust
* North West Genomic Laboratory Hub led by Manchester University NHS Foundation Trust
* North Thames Genomic Laboratory Hub led by Great Ormond Street Hospital for Children NHS Foundation Trust
* South East Genomic Laboratory Hub led by Guy’s and St Thomas’ NHS Foundation Trust
* South West Genomic Laboratory Hub led by North Bristol NHS Trust
* North East and Yorkshire Genomic Laboratory Hub led by The Newcastle upon Tyne Hospitals NHS Foundation Trust

The published dataset includes monthly genomic test activity delivered by the 7 GLHs. This statistic commentary presents activity delivered during Q4 2024-2025 and highlights comparison with Q4 2023-2024 data.

Activity data is shown as the number of reports (“completed pathways”) by the month they were reported in. This is further broken down into cancer and rare disease, and then subcategories as shown within the National Genomic Test Directory.

**Methodology**

This data set is from April 2024 to March 2025 PLCM datasets from all 7 GLHs.

Non-Genomics unit commissioned activity was removed from the data set which includes:

* Screening specialist test group
* Highly Specialised commissioning category
* Specific codes from the 6+1 commissioning group (M3.2, M3.3 and M3.4)
* Test Code M118.1 relating to Chimerism testing (for South West GLH only)

*Note: Test codes for screening and highly specialised groups can be found within the National Genomics Test Directory.*

Activity not related to the testing pathway were removed from the data set which includes:

* Activity related to the storage of samples (R322.1, R346.1, R373.1 and R374.1)

Activity data is based on “testreport” for the count of “completed’ activity.

Categorisation of cancer sub-categories are as indicated in the National Genomic Test Directory split into HaemOnc and Solid Tumour (which is a combination of solid tumour, neurological tumour and CNS as these are all defined as solid tumour).

Identification of paediatric & TYA age bracket for cancer is taken from clinical discussion as patients aged <25 at the point the genomic test is requested.

Categorisation of rare and inherited disease sub-categories are as indicated in the “Specialist Test Group” field within the National Genomic Test Directory.

Identification of paediatric age bracket for rare and inherited disease is taken from clinical discussion as patients aged <18 at the point the genomic test is requested.

For age related brackets, “NULL” data in the age at activity field has been removed.

Activity data for whole genome sequencing has been calculated using the defined technology outlined in the National Genomic Test Directory.

At sub-National breakdowns, any activity that is ≤7 has been replaced with a \* and all other activity has been rounded to the nearest 5 to reduce the risk of identifying individuals from small numbers.

Only valid test codes have been used with this data set. Invalid test codes have been removed from the activity.

For clinical indication code specific data, the following clinical indication codes were used:

* Acute Leukaemia – M80, M81, M89, M90, M91
* Lymphoma – M93, M95, M96, M97, M98, M99, M100, M101, M102, M103, M104, M105, M106, M107, M110, M111, M112, M114, M115, M116, M182, M225
* CNS Cancer – M20, M21, M22, M23, M24, M25, M26, M27, M28, M29, M30, M31, M32, M33, M34, M35, M36, M37, M38, M39, M126, M130, M132, M133, M137, M138, M139, M145, M146, M147, M148, M150, M153, M155, M156, M158, M159, M160, M168, M169, M170, M171, M172, M179, M183, M184, M185, M186, M189, M190, M191, M192, M193, M194, M195, M213
* Sarcoma - M42, M43, M44, M45, M46, M47, M48, M49, M50, M51, M52, M53, M54, M55, M56, M57, M58, M59, M60, M61, M62, M63, M64, M65, M66, M67, M68, M69, M70, M71, M72, M73, M74, M75, M76, M77, M78, M79, M120, M124, M167, M196, M197, M198, M199, M200, M201, M202, M203, M204, M205, M206, M207, M208, M209, M210, M211
* Colorectal Cancer – M1
* Lung Cancer – M4
* Melanoma – M7
* Endometrial Cancer – M215
* Inherited Cancers - R207, R208, R210, R211, R212, R213, R214, R215, R216, R219, R220, R224, R225, R254, R358, R359, R363, R364, R365, R366, R367, R404, R414, R422, R423, R430, R444

**Data availability**

Genomics patient level contract monitoring (PLCM) data used for this publication is based on the M12 2024-2025 (March 2025) data submissions and M12 2024-2025 resubmissions (April 2025), where applicable, from each provider.

East GLH have a significant number of reports at the beginning of 2024-25 that did not have a test code. This means that although the total number of reports will accurately reflect their data, every other category may have a lower value than it should have.

**Revisions**

Revisions on this data is released quarterly as providers submit year to date data each month.

**Glossary**

* **6+1 Commissioning:** Specific tests including NRAS/KRAS, BRAF, KIT testing, ALK testing (1 and 2), Oncotype DX, PD-L1, Prosigna and EnoPredict.
* **Activity:** A count of the number of genomics tests for which test reports have been produced during the month.
* **NHS Genomics Laboratory Hubs (GLH):** A national network of seven NHS Genomics Laboratory Hubs, each responsible for coordinating services for a particular part of the country. More detail on the GLHs can be found here: https://www.england.nhs.uk/genomics/genomic-laboratory-hubs/
* **Highly specialist test:** a test that is commissioned by NHS England as part of a Highly Specialised Service
* **Local point of delivery code:** The code within the PLCM specification that determines the activity stage being reported (see, testprep, testtest and testreport). More details on the current PLCM specification can be found here: <https://www.england.nhs.uk/publication/genomics-testing-reporting-specification/>
* **Paediatric and TYA:** Paediatric and teenagers and young adults which is patients aged <25 at the point the genomic test is requested for cancer activity.
* **Patient Level Contract Monitoring dataset**: a dataset containing patient level identifiers used for analysis and monitoring of contractual information.
* **Specialist Test:** a test that is not provided in all 7 NHS Genomic Laboratory Hubs due to low volume of genomic tests undertaken for the condition/disorder and/or specialist knowledge required for interpretation of results, aligned to a specialist clinical group (e.g. endocrinology, cardiology etc) and provided by designated NHS Genomic Laboratory Hubs.
* **Testprep:** One of the local points of delivery codes as outlined within the PLCM specification. This represents the “preparation” part of the sample pathway and includes the extraction of DNA/RNA. Testprep activity is not reflected within the published dataset.
* **Testreport:** One of the local points of delivery codes as outlined within the PLCM specification. This represents the dry lab activity from receipt of testing data through to distribution of a final report. Testreport is the activity reflected within the published dataset.
* **Testtest:** One of the local points of delivery codes as outlined within the PLCM specification. This represents the wet lab testing of the prepared sample to the generation of data for interpretation and reporting. Testtest activity is not reflected within the published dataset.
* **Year to date:** refers to the period of time beginning the first day of the current financial year up to a specified date.

**Feedback Welcomed**

We welcome feedback on this publication. If anyone has any comments on this, or any other issues regarding Genomics data and statistics, then please contact us at england.genomics@nhs.net

**Additional Information**

For press enquiries contact the NHS England Media team on 0113 825 0958 or 0113 825 0959. Email enquiries should be directed to nhsengland.media@nhs.net

The Genomics Unit data analyst with overall responsibility for the data in this report is:

Joseph Firmin
Genomics Unit
NHS England
Wellington House, 133-155 Waterloo Road, London, SE1 8UG
Email: england.genomics@nhs.net